Seven years after licensing BTK inhibitor from Biogen, beleaguered pennystock biotech partner concedes defeat
A BTK inhibitor Biogen punted out of its pipeline years ago has flopped its first clinical test.
Sunesis Pharma said it would not be taking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
